Holen Sie sich die Stockscreener-App
4.895
4.11%
-0.21
Handel nachbörslich:
4.86
-0.035
-0.72%
Schlusskurs vom Vortag:
$5.105
Offen:
$5.21
24-Stunden-Volumen:
923.99K
Relative Volume:
1.10
Marktkapitalisierung:
$268.71M
Einnahmen:
$124.00K
Nettoeinkommen (Verlust:
$-49.99M
KGV:
-2.8964
EPS:
-1.69
Netto-Cashflow:
$-31.03M
1W Leistung:
-15.89%
1M Leistung:
-22.42%
6M Leistung:
-37.88%
1J Leistung:
-19.49%
1-Tages-Spanne:
$4.83
$5.2188
1-Wochen-Bereich:
$4.83
$6.0395
52-Wochen-Spanne:
$3.785
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Firmenname
Candel Therapeutics Inc
Sektor
Branche
Telefon
617-916-5445
Adresse
117 KENDRICK STREET, NEEDHAM
Vergleichen Sie CADL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
4.895 | 321.69M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-20 | Eingeleitet | Citigroup | Buy |
| 2025-02-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-02-07 | Eingeleitet | BofA Securities | Buy |
| 2022-12-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-08-23 | Eingeleitet | Credit Suisse | Outperform |
| 2021-08-23 | Eingeleitet | Jefferies | Buy |
| 2021-08-23 | Eingeleitet | UBS | Buy |
Alle ansehen
Candel Therapeutics Inc Aktie (CADL) Neueste Nachrichten
Candel Therapeutics: Assessing the Impact of BofA's Downgrade on a Promising Biotech - AInvest
Candel Therapeutics Falls After Downgrade From BofA Securities - MarketScreener
Erasca, Candle, Xencor drop as BofA downgrades (ERAS:NASDAQ) - Seeking Alpha
What does recent volatility data suggest for Candel Therapeutics Inc.Forecast Cut & AI Enhanced Trade Execution Alerts - Newser
Candel Therapeutics Downgraded to Neutral by B of A Securities - AInvest
Pattern recognition hints at Candel Therapeutics Inc. upside - Newser
Price action breakdown for Candel Therapeutics Inc.July 2025 Selloffs & Precise Swing Trade Alerts - Newser
What momentum shifts mean for Candel Therapeutics Inc.July 2025 Weekly Recap & Trade Opportunity Analysis - Newser
BofA Securities Downgrades Candel Therapeutics to Neutral From Buy - MarketScreener
Multi asset correlation models including Candel Therapeutics Inc.2025 Market Trends & Safe Swing Trade Setups - Newser
Will Candel Therapeutics Inc. benefit from macro trendsJobs Report & Smart Swing Trading Alerts - Newser
Chart based analysis of Candel Therapeutics Inc. trends2025 Analyst Calls & Capital Protection Trading Alerts - Newser
How to track smart money flows in Candel Therapeutics Inc.2025 Trading Volume Trends & Fast Gain Stock Trading Tips - Newser
How high can Candel Therapeutics Inc. stock goWeekly Profit Recap & Pattern Based Trade Signal System - Newser
How hedge fund analytics apply to Candel Therapeutics Inc. stockJuly 2025 Opening Moves & Consistent Income Trade Ideas - Newser
Candel Therapeutics shares rise 1.71% after-hours after appointing renowned immunotherapy expert Carl H. June to its Research Advisory Board. - AInvest
Rally Mode: Is Candel Therapeutics Inc. forming bullish engulfing patternsJuly 2025 Macro Moves & AI Powered Market Entry Strategies - khodrobank.com
Small Cap Stocks Gain Traction: MustGrow Biologics, Ocean Power Technologies, Medicus Pharma, Candel Therapeutics, Digi Power X, and G Mining Ventures Lead the Way - AInvest
Candel Therapeutics Inc. stock daily chart insightsMarket Activity Summary & Breakout Confirmation Alerts - Newser
Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board - The Manila Times
FDA-Approved CAR-T Pioneer Carl June Joins Candel Therapeutics to Guide Cancer Immunotherapy Development - Stock Titan
Live market analysis of Candel Therapeutics Inc.July 2025 Selloffs & Weekly Watchlist for Consistent Profits - Newser
Will Candel Therapeutics Inc. face regulatory challengesJuly 2025 Short Interest & Stepwise Trade Execution Plans - khodrobank.com
Published on: 2025-09-02 07:27:55 - beatles.ru
Using data models to predict Candel Therapeutics Inc. stock movement2025 Trade Ideas & High Win Rate Trade Tips - Newser
Is Candel Therapeutics Inc. a play on infrastructure spendingJuly 2025 Breakouts & Real-Time Volume Spike Alerts - khodrobank.com
Is Candel Therapeutics Inc. stock entering bullish territory2025 Dividend Review & Technical Buy Zone Confirmation - Newser
Can Candel Therapeutics Inc. expand its profit margins2025 Investor Takeaways & Low Drawdown Momentum Trade Ideas - khodrobank.com
Advanced analytics toolkit walkthrough for Candel Therapeutics Inc.2025 Trading Recap & Daily Entry Point Trade Alerts - Newser
Multi asset correlation models including Candel Therapeutics IncJuly 2025 Weekly Recap & Community Supported Trade Ideas - Newser
What indicators show strength in Candel Therapeutics Inc.Weekly Trend Report & Verified Technical Trade Signals - Newser
Trend Dashboard Flags Candel Therapeutics Inc. As Potential Swing TradeJuly 2025 Movers & Long-Term Capital Growth Strategies - beatles.ru
Finanzdaten der Candel Therapeutics Inc-Aktie (CADL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Candel Therapeutics Inc-Aktie (CADL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nichols William Garrett | Chief Medical Officer |
Jul 28 '25 |
Sale |
6.98 |
937 |
6,540 |
52,493 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Option Exercise |
1.29 |
781 |
1,007 |
53,274 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Sale |
5.04 |
781 |
3,936 |
52,493 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):